Anteris Technologies (AVR) Q1 2026 TU earnings summary

Executive summary

• Report covers the quarter ended 31 March 2026, prepared under U.S. GAAP and denominated in USD.

• Focus on development and commercialization of medical devices for structural heart disease, notably the DurAVRⓇ Transcatheter Heart Valve.

Significant events and developments

• DurAVRⓇ THV, a biomimetic valve using patented ADAPTⓇ tissue, has been used in over 55,000 patients globally and is FDA-cleared.

• The DurAVRⓇ THV System includes the valve, ADAPTⓇ tissue, and ComASURⓇ Delivery System.

Capital allocation and financing

• Aggregate payments to related parties and associates totaled US$2.3 million in Q1 2026, covering director fees and executive compensation, included in operating cash flows.